Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes

ClinicalTrials.gov ID: NCT01007110

Public ClinicalTrials.gov record NCT01007110. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

The Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

DHA, a type of fatty acid, is important in early development, both in terms of reproductive physiology of gestation and in postnatal behavioral and cognitive function. In adults, DHA has been shown to lower triglycerides and is important to cardiovascular health and autonomic control, lowering heart rate and blood pressure and increasing heart variability. Little is known about how fatty acids impact cardiac control in infants, children or the fetus. Our hypothesis is that maternal DHA supplementation (600 mg/day) will lower fetal HR and increase fetal HRV.

Study identification

NCT ID
NCT01007110
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
University of Kansas
Other
Enrollment
67 participants

Conditions and interventions

Conditions

Interventions

Dietary Supplement · Other

Eligibility (public fields only)

Age range
16 Years to 35 Years
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 2009 (Type not available)
Primary completion
May 2011 (Actual)
Completion
Jul 2011 (Actual)
Last update posted
Jun 9, 2014

2009 – 2011

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
University of Kansas Medical Center Kansas City Kansas 66160 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01007110, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 9, 2014 · Synced Oct 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01007110 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →